This innovative Houston company has the national spotlight this week. Courtesy of re:3D

A Houston company has been announced among the winners of an inaugural seed fund expo competition.

Twelve startups were announced across four categories in the U.S. Small Business Administration's inaugural America’s Seed Fund Startup Expo 2022, which is taking place virtually Wednesday, May 25, from 11:30 am to 3:30 pm. Each of the 12 companies have developed innovative technologies with the help of SBIR grants.

“Every day, in communities across America, entrepreneurs are solving our nation’s most pressing challenges from climate change to feeding and healing the world. The SBA is committed to helping ensure that those ideas receive the necessary support from federal programs and innovation ecosystems so that they can commercialize and grow into resilient businesses,” says Administrator Isabella Casillas Guzman in a news release.

“With the launch of America's Seed Fund Expo, we will showcase exceptional entrepreneurs who have leveraged federal research and development funding through the SBIR Program in key industries and connect them to resources to advance their game-changing innovations right here in America,” she continues.

Houston-based Re:3D is among the companies selected to present at the expo. The complete list of participating companies is as follows:

  • AgTech and Food Security
    • General Probiotics (Saint Paul, MN)
    • Nucleic Sensing Systems (Saint Paul, MN)
    • Shellfish Solutions d/b/a Blue Trace (Castine, ME)
  • Climate and Energy
    • Amorphic Tech (Allentown, PA)
    • FGC Plasma Solutions (Middleton, MA)
    • Hydroplane (Lancaster, CA)
  • National Security and Defense
    • BadVR (Pacoima, CA)
    • Enduralock (Lenexa, KS)
    • PSYONIC (Champaign, IL)
  • Supply Chain Resiliency
    • Chromatic 3D Materials (Golden Valley, MN)
    • Delta Development Team (Tucson, AZ)
    • Re:3D (Houston, TX)

“The giants of future industries so often start as small business startups with big ideas," says Bailey DeVries, associate administrator of the office of investment and innovation, in the news release. "We know the public and private sectors must work together to nurture these small businesses with big ideas over many years so they may sustain and grow. America’s Seed Fund Startup Expo will lift up big ideas and provide a platform for our national innovation community to support the businesses of tomorrow."

The event is free to attend virtually, and anyone can register online at https://bit.ly/SeedFundExpoRSVP. The America’s Seed Fund is among the Small Business Innovation Research and Small Business Technology Transfer programs and is collaborates with 11 federal agencies, that collectively support more than $4 billion a year in federal research and development funding.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."